Article info

Download PDFPDF
Randomised controlled trial
Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection

Authors

  1. Correspondence to Mark Danta
    Department of Medicine, UNSW, Level 5 deLacy Building, Darlinghurst, Sydney, NSW 2016, Australia; m.danta{at}unsw.edu.au
View Full Text

Citation

Danta M
Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection

Publication history

  • First published January 31, 2012.
Online issue publication 
September 20, 2012

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.